Shobha N Joshi1. 1. Multi-Organ Transplant Institute, Ochsner Clinic Foundation, New Orleans, LA and Tulane University School of Medicine, New Orleans, LA.
Abstract
BACKGROUND: Hepatitis C screening is now recommended for all individuals born between the years 1945-1965 in addition to individuals who have high-risk factors. Although most clinicians have extensive experience with the diagnosis and treatment of the disease, they have limited experience screening for it. METHODS: We report current screening guidelines and methods. RESULTS: By identifying the disease as early as possible, screening and treatment can reduce morbidity and mortality. CONCLUSION: Screening for hepatitis C leads to the appropriate evaluation and treatment of individuals chronically infected with the hepatitis C virus and prevents the progression of liver disease to cirrhosis, hepatocellular carcinoma, and the associated morbidity and mortality. Screening for hepatitis C is also cost effective.
BACKGROUND:Hepatitis C screening is now recommended for all individuals born between the years 1945-1965 in addition to individuals who have high-risk factors. Although most clinicians have extensive experience with the diagnosis and treatment of the disease, they have limited experience screening for it. METHODS: We report current screening guidelines and methods. RESULTS: By identifying the disease as early as possible, screening and treatment can reduce morbidity and mortality. CONCLUSION: Screening for hepatitis C leads to the appropriate evaluation and treatment of individuals chronically infected with the hepatitis C virus and prevents the progression of liver disease to cirrhosis, hepatocellular carcinoma, and the associated morbidity and mortality. Screening for hepatitis C is also cost effective.
Entities:
Keywords:
Carcinoma–hepatocellular; hepatitis C antibodies; hepatitis C virus; hepatitis C–chronic; liver cirrhosis
Authors: Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole Journal: Clin Gastroenterol Hepatol Date: 2011-03-11 Impact factor: 11.382
Authors: R M Ghobrial; D G Farmer; A Baquerizo; S Colquhoun; H R Rosen; H Yersiz; J F Markmann; K E Drazan; C Holt; D Imagawa; L I Goldstein; P Martin; R W Busuttil Journal: Ann Surg Date: 1999-06 Impact factor: 12.969
Authors: Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane Journal: N Engl J Med Date: 2013-04-23 Impact factor: 91.245
Authors: Stefan Zeuzem; Thomas Berg; Edward Gane; Peter Ferenci; Graham R Foster; Michael W Fried; Christophe Hezode; Gideon M Hirschfield; Ira Jacobson; Igor Nikitin; Paul J Pockros; Fred Poordad; Jane Scott; Oliver Lenz; Monika Peeters; Vanitha Sekar; Goedele De Smedt; Rekha Sinha; Maria Beumont-Mauviel Journal: Gastroenterology Date: 2013-11-01 Impact factor: 22.682
Authors: Hope King; J E Soh; William W Thompson; Jessica Rogers Brown; Karina Rapposelli; Claudia Vellozzi Journal: Public Health Rep Date: 2021-10-04 Impact factor: 3.117
Authors: Monica L Kasting; Anna R Giuliano; Richard R Reich; Richard G Roetzheim; David R Nelson; Elizabeth Shenkman; Susan T Vadaparampil Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-03-27 Impact factor: 4.254